Current efforts address the targeting of common genetic alterations such as TP53 mutations, which are found in 70% of COAD [33], by humoral and cell-based immunotherapies, including T cell receptor mimic monoclonal antibodies [34]. Here, TP53 is linked to colon adenocarcinoma.